In the non-treated (anti-HER2 therapy-naive) patients, HER2 IHC 3 + BC patients had significantly shorter BCSS (mean value 84 months) compared to patients with IHC 2 + /Amplified tumours (mean value 119 months), (P = 0.01). This evidence concerns the gene ERBB2 and breast cancer.